OUR TEAM
Experienced Leadership
Oncodrug is led by drug discovery experts with proven track records in progressing projects from target validation through to clinical trials.
Founder & CEO
Caroline has over 30 years experience in drug discovery and translational research.
Caroline is Founder, CSO, COO and Director of MyT Bioscience. She is also Founder and CEO of Oncodrug, and was Founder of EPTTCO and Proacta.
Caroline obtained a BSc in Chemistry and a PhD in Biological Chemistry from University College London. She is recognised by the Team Science Award (2012, AACR).
Caroline was appointed Professor in 2000. She is a Fellow of the Royal Society of Chemistry (1999) and the Royal Society of Biology (2010).
Founder & CSO
Richard has over 30 years of experience in cell signalling, cancer biology and translational research.
Richard is Founder and CEO of MyT Bioscience. He is also Founder and CSO of Oncodrug, and was Founder of EPTTCO and Proacta.
Richard obtained a BSc in Genetics and Microbiology from University College, London, and a PhD in Biochemistry from Imperial College, London. He is recognised by multiple prizes and awards, including Estella Medrano Memorial Award (2011, SMR), the Team Science Award (2012, AACR), the Leopold Gruffuel Prize (2016) and the Fritz Anders Medal (2016).
Richard was appointed Member of EMBO (2009) and Academia Europeae (2015). He is a Fellow of the Academy of Medical Sciences (FMedSci) (2008), the European Academy of Cancer Sciences (2009), the Royal Society of Biology (FRBS) (2011) and the Royal Society (FRS) (2018).
Advisor
Mr Julian H. Lewis is advisor to the Oncodrug board. He is on the Board of Directors at Lewis Foundation Holdings Ltd, Lewis Trust Group Ltd plus multiple international companies.
Mr. Lewis has significant experience in investment management, both in the UK and worldwide. He is a member of the Chartered Institute for Securities and Investment (CISI) and holds the MCSI qualification and has been a Fellow of the Association of Chartered Certified Accountants since 1998 and is a Chartered Wealth Manager.
Head of Chemistry
Dan has over 30 years of experience in medicinal chemistry and drug discovery, along with substantial expertise in intellectual property strategy and management.
He joined Oncodrug following five years at the CRUK-MI DDU, where he served as Head of Chemistry. Before that, he worked at The Institute of Cancer Research in London on a variety of medicinal chemistry and chemical biology projects.
Dan obtained a PhD in Medicinal Chemistry from the University of London.
Head of Discovery
Leo has over 20 years of experience in drug discovery. Prior to joining Oncodrug, he has worked in the CRUK Manchester Institute and The Institute of Cancer Research on a range of projects. In addition to his drug discovery expertise, Leo has extensive experience in medicinal chemistry, pharmacokinetics and bioanalysis.
Founder & CEO
Caroline has over 30 years experience in drug discovery and translational research.
Caroline is Founder, CSO, COO and Director of MyT Bioscience. She is also Founder and CEO of Oncodrug, and was Founder of EPTTCO and Proacta.
Caroline obtained a BSc in Chemistry and a PhD in Biological Chemistry from University College London. She is recognised by the Team Science Award (2012, AACR).
Caroline was appointed Professor in 2000. She is a Fellow of the Royal Society of Chemistry (1999) and the Royal Society of Biology (2010).
Founder & CSO
Richard has over 30 years of experience in cell signalling, cancer biology and translational research.
Richard is Founder and CEO of MyT Bioscience. He is also Founder and CSO of Oncodrug, and was Founder of EPTTCO and Proacta.
Richard obtained a BSc in Genetics and Microbiology from University College, London, and a PhD in Biochemistry from Imperial College, London. He is recognised by multiple prizes and awards, including Estella Medrano Memorial Award (2011, SMR), the Team Science Award (2012, AACR), the Leopold Gruffuel Prize (2016) and the Fritz Anders Medal (2016).
Richard was appointed Member of EMBO (2009) and Academia Europeae (2015). He is a Fellow of the Academy of Medical Sciences (FMedSci) (2008), the European Academy of Cancer Sciences (2009), the Royal Society of Biology (FRBS) (2011) and the Royal Society (FRS) (2018).
Advisor
Mr Julian H. Lewis is advisor to the Oncodrug board. He is on the Board of Directors at Lewis Foundation Holdings Ltd, Lewis Trust Group Ltd plus multiple international companies.
Mr. Lewis has significant experience in investment management, both in the UK and worldwide. He is a member of the Chartered Institute for Securities and Investment (CISI) and holds the MCSI qualification and has been a Fellow of the Association of Chartered Certified Accountants since 1998 and is a Chartered Wealth Manager.
Head of Chemistry
Dan has over 30 years of experience in medicinal chemistry and drug discovery, along with substantial expertise in intellectual property strategy and management.
He joined Oncodrug following five years at the CRUK-MI DDU, where he served as Head of Chemistry. Before that, he worked at The Institute of Cancer Research in London on a variety of medicinal chemistry and chemical biology projects.
Dan obtained a PhD in Medicinal Chemistry from the University of London.
Head of Discovery
Leo has over 20 years of experience in drug discovery. Prior to joining Oncodrug, he has worked in the CRUK Manchester Institute and The Institute of Cancer Research on a range of projects. In addition to his drug discovery expertise, Leo has extensive experience in medicinal chemistry, pharmacokinetics and bioanalysis.
Founder & CEO
Caroline has over 30 years experience in drug discovery and translational research.
Caroline is Founder, CSO, COO and Director of MyT Bioscience. She is also Founder and CEO of Oncodrug, and was Founder of EPTTCO and Proacta.
Caroline obtained a BSc in Chemistry and a PhD in Biological Chemistry from University College London. She is recognised by the Team Science Award (2012, AACR).
Caroline was appointed Professor in 2000. She is a Fellow of the Royal Society of Chemistry (1999) and the Royal Society of Biology (2010).
Founder & CSO
Richard has over 30 years of experience in cell signalling, cancer biology and translational research.
Richard is Founder and CEO of MyT Bioscience. He is also Founder and CSO of Oncodrug, and was Founder of EPTTCO and Proacta.
Richard obtained a BSc in Genetics and Microbiology from University College, London, and a PhD in Biochemistry from Imperial College, London. He is recognised by multiple prizes and awards, including Estella Medrano Memorial Award (2011, SMR), the Team Science Award (2012, AACR), the Leopold Gruffuel Prize (2016) and the Fritz Anders Medal (2016).
Richard was appointed Member of EMBO (2009) and Academia Europeae (2015). He is a Fellow of the Academy of Medical Sciences (FMedSci) (2008), the European Academy of Cancer Sciences (2009), the Royal Society of Biology (FRBS) (2011) and the Royal Society (FRS) (2018).
Advisor
Mr Julian H. Lewis is advisor to the Oncodrug board. He is on the Board of Directors at Lewis Foundation Holdings Ltd, Lewis Trust Group Ltd plus multiple international companies.
Mr. Lewis has significant experience in investment management, both in the UK and worldwide. He is a member of the Chartered Institute for Securities and Investment (CISI) and holds the MCSI qualification and has been a Fellow of the Association of Chartered Certified Accountants since 1998 and is a Chartered Wealth Manager.
Head of Chemistry
Dan has over 30 years of experience in medicinal chemistry and drug discovery, along with substantial expertise in intellectual property strategy and management.
He joined Oncodrug following five years at the CRUK-MI DDU, where he served as Head of Chemistry. Before that, he worked at The Institute of Cancer Research in London on a variety of medicinal chemistry and chemical biology projects.
Dan obtained a PhD in Medicinal Chemistry from the University of London.
Head of Discovery
Leo has over 20 years of experience in drug discovery. Prior to joining Oncodrug, he has worked in the CRUK Manchester Institute and The Institute of Cancer Research on a range of projects. In addition to his drug discovery expertise, Leo has extensive experience in medicinal chemistry, pharmacokinetics and bioanalysis.
